Research Journal

The emergence of CMLase — an engineered enzyme reported to convert protein-associated Nε-carboxymethyl-lysine (CML) back to lysine under controlled experimental conditions — created a new scientific starting point. A stable form of accumulated protein chemical damage can now be investigated as a direct enzymatic target.

Panacea Bio Chem is conducting an independent research programme into CMLase, enzymatic protein repair, formulation, stabilisation and related molecular-repair technologies. The objective is not to repeat existing research, but to develop, stabilise, formulate and integrate the principle with other Panacea technologies: enzyme stabilisation, oxidation control, low-temperature formulation, delivery architecture, molecular accessibility, reaction by-product management, functional restoration and wider enzymatic repair.

CMLase.org will document this programme, publish Panacea’s scientific perspective and present future research findings as they become available. The original CrGO-897/CMLase enzyme was reported by external researchers; Panacea Bio Chem does not claim authorship or ownership of that original discovery.

CML — Nε-carboxymethyl-lysine — is a stable advanced glycation end-product that forms non-enzymatically and can accumulate on long-lived proteins. Until recently, such accumulated modifications were treated as effectively permanent.

External researchers reported CrGO-897, an enzyme developed from a glycine-oxidase scaffold through computational design, screening and directed evolution. Under controlled laboratory conditions, the enzyme was shown to convert protein-associated CML back into lysine, acting on model proteins, on isolated human lens proteins and in prepared human arterial and skin tissue samples. The reaction processes the carboxymethyl group oxidatively, generating glyoxylate and hydrogen peroxide.

The finding is a proof of concept: a stable form of accumulated protein chemical damage can be directly targeted through engineered enzymatic chemistry. CMLase reverses one specific chemical modification — it is not currently shown to reverse every AGE, every protein cross-link or ageing as a whole.

The CMLase principle combines three elements: a defined chemical lesion that accumulates on proteins, an engineered active site that recognises that lesion, and a catalytic reaction that restores the original residue. Each element is, in principle, transferable.

The hypothesis under consideration at Panacea Bio Chem is that wider enzymatic repair systems — targeting other accumulated modifications beyond CML — could be approached through the same combination of computational design, screening and directed evolution, coupled with formulation, stabilisation and delivery technologies developed across the Panacea platform.

This is a research direction, not a result. No enzyme beyond the published CrGO-897 work is claimed, and no activity against any other modification has been demonstrated by Panacea Bio Chem at this time.